The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Zorkina Y.A.

Serbsky National Medical Research Center of Psychiatry and Narcology;
Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department

Morozova I.O.

Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department

Abramova O.V.

Serbsky National Medical Research Center of Psychiatry and Narcology;
Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department

Ochneva A.G.

Serbsky National Medical Research Center of Psychiatry and Narcology;
Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department

Gankina O.A.

Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department;
Russian Medical Academy of Continuous Professional Education

Andryushenko A.V.

Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department;
Lomonosov Moscow State University

Kurmyshev M.V.

Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department

Kostyuk G.P.

Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department

Morozova A.Yu.

Serbsky National Medical Research Center of Psychiatry and Narcology;
Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department

Use of modern classification systems for complex diagnostics of Alzheimer’s disease

Authors:

Zorkina Y.A., Morozova I.O., Abramova O.V., Ochneva A.G., Gankina O.A., Andryushenko A.V., Kurmyshev M.V., Kostyuk G.P., Morozova A.Yu.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(1): 121‑127

DOI: 10.17116/jnevro2024124011121

Views: 1267

Downloaded: 8

Buy for 200₽
Contact the author
Table of contents

To cite this article:

Zorkina YA, Morozova IO, Abramova OV, et al. . Use of modern classification systems for complex diagnostics of Alzheimer’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(1):121‑127. (In Russ.)
https://doi.org/10.17116/jnevro2024124011121

Подписка 2025 (S.S. Korsakov Journal of Neurology and Psychiatry)
 
МСФ на ЯМ
Close metadata

OBJECTIVE

To compare the content of β-amyloid (Aβ) peptides Aβ40, Aβ42, total and threonine phosphorylated 181 tau-protein in cerebrospinal fluid (CSF) of patients with the clinical diagnosis of Alzheimer’s disease (AD).

MATERIAL AND METHODS

The study was performed on 64 patients with a diagnosis of dementia and MMSE scores of 24 or lower. All patients underwent lumbar puncture. Aβ40, Aβ42, Aβ42/40 ratio, total tau, phosphorylated tau at threonine 181 were determined in the CSF using a multiplex assay according to the manufacturer’s protocol, the concentration was determined in pkg/ml.

RESULTS

The preliminary diagnosis of AD was made in 3 patients (5%). As a result of the study of protein content in the CSF, signs of AD were detected in 48 (75%) people. The findings suggest that the diagnosis of AD is made 10—14 times less frequently than it should be according to the World Health Organization data. The discrepancy between clinical diagnosis and laboratory findings is confirmed by our study.

CONCLUSION

Differences in the therapy of dementias and the development of new drugs targeting specific links in the pathogenesis of different types of dementias require accurate and complete diagnosis of dementias, especially AD, as the most common type of dementia.

Keywords:

dementia
cerebrospinal fluid
beta-amyloid
tau-protein

Authors:

Zorkina Y.A.

Serbsky National Medical Research Center of Psychiatry and Narcology;
Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department

Morozova I.O.

Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department

Abramova O.V.

Serbsky National Medical Research Center of Psychiatry and Narcology;
Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department

Ochneva A.G.

Serbsky National Medical Research Center of Psychiatry and Narcology;
Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department

Gankina O.A.

Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department;
Russian Medical Academy of Continuous Professional Education

Andryushenko A.V.

Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department;
Lomonosov Moscow State University

Kurmyshev M.V.

Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department

Kostyuk G.P.

Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department

Morozova A.Yu.

Serbsky National Medical Research Center of Psychiatry and Narcology;
Alexeev Mental-Health Clinic No. 1 of Moscow Healthcare Department

Received:

14.09.2023

Accepted:

16.09.2023

List of references:

  1. Global action plan on the public health response to dementia 2017—2025. Geneva: World Health Organization; 2017. Licence: CC BY-NC-SA 3.0 IGO. 
  2. Jeremic D, Jiménez-Díaz L, Navarro-López JD. Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer’s disease: a systematic review. Ageing Res Rev. 2021;72:101496. https://doi.org/10.1016/j.arr.2021.101496
  3. MacLeod R, Hillert EK, Cameron RT, Baillie GS. The role and therapeutic targeting of α-, β- and γ-secretase in Alzheimer’s disease. Future Sci OA. 2015;1(3):FSO11. https://doi.org/10.4155/fso.15.9
  4. Murphy MP, LeVine H 3rd. Alzheimer’s disease and the amyloid-beta peptide. J Alzheimers Dis. 2010;19(1):311-323.  https://doi.org/10.3233/JAD-2010-1221
  5. Folch J, Ettcheto M, Petrov D, et al. Review of the advances in treatment for Alzheimer disease: Strategies for combating β-amyloid protein. Una revisión de los avances en la terapéutica de la enfermedad de Alzheimer: estrategia frente a la proteína β-amiloide. Neurologia (Engl Ed). 2018;33(1):47-58.  https://doi.org/10.1016/j.nrl.2015.03.012
  6. Grandal Leiros B, Pérez Méndez LI, Zelaya Huerta MV, et al. Prevalence and concordance between the clinical and the post-mortem diagnosis of dementia in a psychogeriatric clinic. Prevalencia y concordancia entre diagnóstico clínico y anatomopatológico de demencia en una clínica psicogeriátrica. Neurologia (Engl Ed). 2018;33(1):13-17.  https://doi.org/10.1016/j.nrl.2016.04.011
  7. Selvackadunco S, Langford K, Shah Z, et al. Comparison of clinical and neuropathological diagnoses of neurodegenerative diseases in two centres from the Brains for Dementia Research (BDR) cohort. J Neural Transm (Vienna). 2019;126(3):327-337.  https://doi.org/10.1007/s00702-018-01967-w
  8. Sengupta U, Kayed R. Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases. Prog Neurobiol. 2022;214:102270. https://doi.org/10.1016/j.pneurobio.2022.102270
  9. Sunderland T, Linker G, Mirza N, et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA. 2003;289(16):2094-2103. https://doi.org/10.1001/jama.289.16.2094
  10. Li RX, Ma YH, Tan L, Yu JT. Prospective biomarkers of Alzheimer’s disease: A systematic review and meta-analysis. Ageing Res Rev. 2022;81:101699. https://doi.org/10.1016/j.arr.2022.101699
  11. Mielke MM, Frank RD, Dage JL, et al. Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes. JAMA Neurol. 2021;78(9):1108-1117. https://doi.org/10.1001/jamaneurol.2021.2293
  12. Folstein MF, Folstein SE, McHugh PR. «Mini-mental state». A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198.  https://doi.org/10.1016/0022-3956(75)90026-6
  13. Ebenau JL, Timmers T, Wesselman LMP, et al. ATN classification and clinical progression in subjective cognitive decline: The SCIENCe project. Neurology. 2020;95(1):e46-e58.  https://doi.org/10.1212/WNL.0000000000009724
  14. Hansen EO, Dias NS, Burgos ICB, et al. Millipore xMap® Luminex (HATMAG-68K): An Accurate and Cost-Effective Method for Evaluating Alzheimer’s Biomarkers in Cerebrospinal Fluid. Front Psychiatry. 2021;12:716686. https://doi.org/10.3389/fpsyt.2021.716686.
  15. Constantinides VC, Boufidou F, Bourbouli M, et al. Application of the AT(N) and Other CSF Classification Systems in Behavioral Variant Frontotemporal Dementia. Diagnostics (Basel). 2023;13(3):332.  https://doi.org/10.3390/diagnostics13030332.
  16. Jack CR Jr, Bennett DA, Blennow K, et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539-547.  https://doi.org/10.1212/WNL.0000000000002923
  17. Milà-Alomà M, Salvadó G, Gispert JD, et al. Amyloid beta, tau, synaptic, neurodegeneration, and glial biomarkers in the preclinical stage of the Alzheimer’s continuum. Alzheimers Dement. 2020;16(10):1358-1371. https://doi.org/10.1002/alz.12131
  18. Bogolepova AN, Vasenina EE, Gomzyakova NA, et al. Clinical Guidelines for Cognitive Disorders in Elderly and Older Patients. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2021;121(10-3):6-137. (In Russ.). https://doi.org/10.17116/jnevro20211211036
  19. Hasani SA, Mayeli M, Salehi MA, Barzegar Parizi R. A Systematic Review of the Association between Amyloid-β and τ Pathology with Functional Connectivity Alterations in the Alzheimer Dementia Spectrum Utilizing PET Scan and rsfMRI. Dement Geriatr Cogn Dis Extra. 2021;11(2):78-90.  https://doi.org/10.1159/000516164
  20. Resnick SM, Sojkova J. Amyloid imaging and memory change for prediction of cognitive impairment. Alzheimers Res Ther. 2011;3(1):3.  https://doi.org/10.1186/alzrt62
  21. Jellinger KA, Attems J. Prevalence and pathology of vascular dementia in the oldest-old. J Alzheimers Dis. 2010;21(4):1283-1293. https://doi.org/10.3233/jad-2010-100603
  22. Levin OS, Trusova NA. Vascular risk factors for Alzheimer’s disease. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2013;113(7 Pt 2):3-12. (In Russ.).
  23. Zakharov VV. Differential Diagnosis of Cognitive Impairments. Effektivnaya farmakoterapiya. Nevrologiya. 2014;(3):25. (In Russ.).
  24. Fierini F. Mixed dementia: Neglected clinical entity or nosographic artifice? J Neurol Sci. 2020;410:116662. https://doi.org/10.1016/j.jns.2019.116662
  25. Apátiga-Pérez R, Soto-Rojas LO, Campa-Córdoba BB, et al. Neurovascular dysfunction and vascular amyloid accumulation as early events in Alzheimer’s disease. Metab Brain Dis. 2022;37(1):39-50.  https://doi.org/10.1007/s11011-021-00814-4
  26. Badimon A, Torrente D, Norris EH. Vascular Dysfunction in Alzheimer’s Disease: Alterations in the Plasma Contact and Fibrinolytic Systems. Int J Mol Sci. 2023;24(8):7046. https://doi.org/10.3390/ijms24087046
  27. Hort J, O’Brien JT, Gainotti G, et al. EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur J Neurol. 2010;17(10):1236-1248. https://doi.org/10.1111/j.1468-1331.2010.03040.x
  28. Gavrilova SI, Kolykhalov IV, Kulik AS, et al. Clinical experience of the use of memantal in patients with moderate and severe Alzheimer’s disease. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2016;116(2):52-57. (In Russ.). https://doi.org/10.17116/jnevro20161162152-57
  29. Olivares D, Deshpande VK, Shi Y, et al. N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer’s disease, vascular dementia and Parkinson’s disease. Curr Alzheimer Res. 2012;9(6):746-758.  https://doi.org/10.2174/156720512801322564
  30. Kokkinou M, Beishon LC, Smailagic N, et al. Plasma and cerebrospinal fluid ABeta42 for the differential diagnosis of Alzheimer’s disease dementia in participants diagnosed with any dementia subtype in a specialist care setting. Cochrane Database Syst Rev. 2021;2(2):CD010945. https://doi.org/10.1002/14651858.CD010945.pub2

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register


We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.